MedTrace Logo

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

NCT06074549 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-08-28

No results posted yet for this study

Summary

The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.

Conditions

Interventions

DEVICE

DynamX Novolimus-eluting Coronary Bioadaptor System

All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use

Sponsors & Collaborators

  • Elixir Medical Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-10
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • Austria
  • Curacao
  • Indonesia
  • Italy
  • Jordan
  • Saudi Arabia
  • Turkey (Türkiye)
  • United Arab Emirates
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06074549 on ClinicalTrials.gov